Itamar Willner | Medicinal Chemistry | Excellence in Research Award

Posted on by ScienceFather

Prof. Itamar Willner | Medicinal Chemistry | Excellence in Research Award

Professor from The Hebrew University of Jerusalem, Israel

Professor Itamar Willner is a distinguished Israeli chemist renowned for his pioneering contributions to supramolecular chemistry, nanotechnology, and nanobiotechnology. Born in January 1947, he has been a faculty member at the Hebrew University of Jerusalem since 1981 and was appointed as a full professor in 1986. His research has significantly advanced the understanding and application of molecular self-assembly, DNA nanotechnology, and bio-hybrid systems. With over 890 scientific publications and more than 100,000 citations, Professor Willner is among the most cited chemists globally, reflecting the profound impact of his work on the scientific community. His innovative approaches have led to the development of DNA-based molecular machines, logic gates, and dynamic networks, bridging the gap between chemistry, biology, and materials science. Throughout his career, he has received numerous prestigious awards, including the Israel Prize in Chemistry, the Rothschild Prize, and the EMET Prize, acknowledging his exceptional contributions to science. Professor Willner’s leadership extends beyond research; he has played pivotal roles in various scientific committees and editorial boards, fostering international collaborations and mentoring the next generation of scientists. His work continues to influence diverse fields, from artificial photosynthesis to smart materials, underscoring his status as a leading figure in contemporary chemistry.

Professional Profile

Education

Professor Willner’s academic journey commenced with a B.Sc. in Chemistry and Physics from the Hebrew University of Jerusalem, completed with distinction. He further pursued an M.Sc. in Chemistry at the same institution, again graduating with distinction. In 1978, he earned his Ph.D. in Physical Organic Chemistry from the Hebrew University, presenting a thesis titled “Novel Series of Polycyclic Aromatic Ions: Aromaticity Structure Relationships,” which was approved summa cum laude. Following his doctoral studies, Professor Willner undertook postdoctoral research at the University of California, Berkeley, from 1978 to 1980, working under the mentorship of Professor Melvin Calvin. This period was instrumental in shaping his future research directions, particularly in the realms of photochemistry and molecular electronics. His comprehensive educational background laid a robust foundation for his subsequent groundbreaking work in chemistry, enabling him to integrate principles from various sub-disciplines and pioneer interdisciplinary research approaches. The rigorous training and diverse academic experiences he acquired during his formative years have been pivotal in his development as a leading scientist in the field.

Professional Experience

Professor Willner’s professional career is marked by a series of esteemed academic and research positions. After completing his postdoctoral fellowship at UC Berkeley, he served as a Staff Scientist and Adjunct Assistant Professor at the same institution from 1980 to 1981. In 1981, he returned to the Hebrew University of Jerusalem as a Senior Lecturer in the Institute of Chemistry. His academic progression continued with his promotion to Associate Professor in 1983 and subsequently to Full Professor in 1986, a position he holds to this day. Beyond his teaching and research responsibilities, Professor Willner has held several significant administrative roles, including Head of the Institute of Chemistry and Chairman of the Natural Sciences Division of the Israel Academy of Sciences and Humanities. He has also been an active member of numerous scientific advisory boards and editorial committees, contributing to the advancement of chemical sciences globally. His professional journey reflects a steadfast commitment to scientific excellence, education, and leadership within the academic community.

Research Interests

Professor Willner’s research interests are deeply rooted in the exploration of supramolecular chemistry, nanotechnology, and biomolecular systems. His work focuses on the design and synthesis of functional nanostructures, particularly those involving DNA nanotechnology, nanoenzymes, and stimuli-responsive materials. He has been instrumental in developing DNA-based molecular machines and logic gates, contributing to the field of molecular computing. His research extends to the construction of bio-nano hybrid systems, integrating biomacromolecules with inorganic nanoparticles to create novel catalytic and sensing platforms. Additionally, Professor Willner has investigated artificial photosynthesis, aiming to mimic natural energy conversion processes for sustainable applications. His interdisciplinary approach combines principles from chemistry, biology, and materials science, leading to innovations in drug delivery systems, biosensors, and smart materials. Through his extensive research, he continues to push the boundaries of molecular design and functional material development.

Research Skills

Professor Willner possesses a diverse set of research skills that have enabled him to make significant contributions to the field of chemistry. His expertise includes the synthesis and characterization of supramolecular assemblies, development of DNA-based nanostructures, and fabrication of bio-nano hybrid systems. He is proficient in employing various spectroscopic and electrochemical techniques to analyze the properties and behaviors of complex molecular systems. His skills extend to the design of molecular machines and logic devices, leveraging the unique properties of nucleic acids and proteins. Furthermore, Professor Willner is adept at integrating biological components with inorganic materials to create functional interfaces for sensing and catalytic applications. His ability to navigate and combine multiple scientific disciplines has been crucial in advancing research in nanobiotechnology and molecular electronics. These competencies have not only facilitated his own research endeavors but have also positioned him as a mentor and leader in the scientific community.

Awards and Honors

Throughout his illustrious career, Professor Willner has received numerous awards and honors recognizing his outstanding contributions to science. Notably, he was awarded the Israel Prize in Chemistry in 2002, one of the country’s highest honors. His accolades also include the Rothschild Prize in Chemistry (2008), the EMET Prize in Chemistry (2008), and the Max Planck Research Award for International Cooperation (1998). He has been elected as a Fellow of the American Association for the Advancement of Science (1996) and the Royal Society of Chemistry (2009). His membership in prestigious academies includes the Israel Academy of Sciences and Humanities (2002), the European Academy of Sciences and Arts (2004), and the German National Academy of Sciences Leopoldina (2009). These honors reflect his significant impact on the scientific community and his role in advancing chemical research on a global scale.

Conclusion

Professor Itamar Willner’s career embodies the pinnacle of scientific achievement and innovation. His extensive research in supramolecular chemistry, nanotechnology, and biomolecular systems has not only expanded the frontiers of chemical science but has also paved the way for practical applications in medicine, energy, and materials science. His interdisciplinary approach and ability to integrate complex systems have resulted in groundbreaking developments, such as DNA-based molecular machines and artificial photosynthetic systems. Beyond his research, Professor Willner’s commitment to education and mentorship has cultivated a new generation of scientists, further amplifying his impact. His numerous awards and memberships in esteemed scientific academies underscore the global recognition of his contributions. As a leading figure in contemporary chemistry, Professor Willner continues to inspire and drive innovation, solidifying his legacy as a pioneer and visionary in the scientific community.

Publications Top Notes

  • Title: Integrated nanoparticle–biomolecule hybrid systems: synthesis, properties, and applications
    Authors: E. Katz, I. Willner
    Journal: Angewandte Chemie International Edition 43(45), 6042–6108
    Citations: 3189
    Year: 2004

  • Title: Nanoparticle arrays on surfaces for electronic, optical, and sensor applications
    Authors: A.N. Shipway, E. Katz, I. Willner
    Journal: ChemPhysChem 1(1), 18–52
    Citations: 3175
    Year: 2000

  • Title: Probing biomolecular interactions at conductive and semiconductive surfaces by impedance spectroscopy: routes to impedimetric immunosensors, DNA‐sensors, and enzyme biosensors
    Authors: E. Katz, I. Willner
    Journal: Electroanalysis
    Citations: 1648
    Year: 2003

  • Title: “Plugging into enzymes”: Nanowiring of redox enzymes by a gold nanoparticle
    Authors: Y. Xiao, F. Patolsky, E. Katz, J.F. Hainfeld, I. Willner
    Journal: Science 299(5614), 1877–1881
    Citations: 1520
    Year: 2003

  • Title: Diverse applications of nanomedicine
    Authors: B. Pelaz, C. Alexiou, R.A. Alvarez-Puebla, F. Alves, A.M. Andrews, S. Ashraf, …
    Journal: ACS Nano 11(3), 2313–2381
    Citations: 1381
    Year: 2017

  • Title: Integration of layered redox proteins and conductive supports for bioelectronic applications
    Authors: I. Willner, E. Katz
    Journal: Angewandte Chemie International Edition 39(7), 1180–1218
    Citations: 1309
    Year: 2000

  • Title: Biomolecule‐functionalized carbon nanotubes: applications in nanobioelectronics
    Authors: E. Katz, I. Willner
    Journal: ChemPhysChem 5(8), 1084–1104
    Citations: 1089
    Year: 2004

  • Title: Semiconductor quantum dots for bioanalysis
    Authors: R. Gill, M. Zayats, I. Willner
    Journal: Angewandte Chemie International Edition 47(40), 7602–7625
    Citations: 1026
    Year: 2008

  • Title: Electronic aptamer‐based sensors
    Authors: I. Willner, M. Zayats
    Journal: Angewandte Chemie International Edition 46(34), 6408–6418
    Citations: 912
    Year: 2007

  • Title: Electroanalytical and bioelectroanalytical systems based on metal and semiconductor nanoparticles
    Authors: E. Katz, I. Willner, J. Wang
    Journal: Electroanalysis
    Citations: 912
    Year: 2004

Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award

Posted on by ScienceFather

Dr. Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award

Deputy Dean from Perdana University, Malaysia 

Sutha Devaraj is a dedicated researcher and academician with expertise in pharmaceutical sciences, specializing in drug discovery and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences from Universiti Sains Malaysia (USM) in 2018, where her research focused on the development of optimized methods for preparing bioactive fractions of Strobilanthes crispus (L.) Bremek. Her work involved the quantification of the plant’s marker compound, contributing to advancements in natural product-based drug discovery. Before completing her Ph.D., Sutha obtained a Master’s in Pharmacology from USM in 2012. Her master’s thesis focused on the hepatoprotective properties of Curcuma xanthorrhiza Rox, exploring its potential for liver protection through its bioactive compounds. She also holds a B.Sc. (Hons) in Biotechnology from AIMST University, Malaysia, where she graduated with a CGPA of 3.41. This academic foundation in biotechnology provided her with a strong understanding of molecular biology and biochemistry, essential for her later research in pharmacology and drug development. Throughout her career, Sutha has contributed significantly to the study of plant-based compounds with medicinal properties, and her work has enhanced the understanding of their therapeutic potential. Her academic journey has been marked by a consistent focus on integrating practical research with innovative approaches in pharmaceutical sciences.

Professional Profile

Education

Sutha Devaraj’s educational background is distinguished by her specialized studies in pharmaceutical sciences and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences with a focus on Drug Discovery from Universiti Sains Malaysia (USM) in 2018. Her doctoral thesis, titled Development of an Optimized Method for the Preparation of Bioactive Fraction of Strobilanthes crispus (L.) Bremek and the Quantification of its Marker Compound, was instrumental in advancing research on bioactive compounds derived from natural sources. This work enhanced the understanding of the therapeutic potentials of Strobilanthes crispus, contributing to both pharmaceutical science and ethnomedicine. Before completing her Ph.D., Sutha obtained her Master of Science (M.Sc.) in Pharmacology from USM in 2012. Her research focused on the hepatoprotective and pharmacological properties of Curcuma xanthorrhiza Rox, and she published findings related to the effectiveness of its standardized ethanolic extract in protecting the liver, demonstrating her expertise in pharmacological testing and drug development. Sutha’s academic journey began with a Bachelor of Science (B.Sc.) in Biotechnology (Hons) from AIMST University in 2008, where she graduated with a CGPA of 3.41. This early foundation in biotechnology paved the way for her subsequent advanced studies in pharmacology and pharmaceutical sciences.

Professional Experience

Sutha Devaraj has accumulated significant experience in the field of pharmaceutical sciences and pharmacology. Throughout her career, she has worked with various academic and research institutions, where she has contributed to advancing the understanding of pharmacological mechanisms and drug discovery. As a researcher at Universiti Sains Malaysia (USM), Sutha has actively participated in projects focusing on the isolation and quantification of bioactive compounds from plants, which has led to important findings on their therapeutic potentials. She has collaborated with both local and international researchers to examine the pharmacological properties of natural products, a focus that has shaped her work in drug discovery. In addition to her research roles, Sutha has also contributed to teaching and mentoring undergraduate and postgraduate students. She has shared her expertise in pharmacology and biotechnology, helping shape the next generation of scientists. Through her work, Sutha has built a strong professional reputation, earning recognition for her in-depth understanding of drug development processes and her ability to implement novel methodologies in her research.

Research Skills

Sutha Devaraj possesses a wide array of research skills essential to her work in pharmaceutical sciences and pharmacology. Her proficiency in bioactive compound isolation and quantification has been demonstrated through her research on Strobilanthes crispus and Curcuma xanthorrhiza, both of which are significant to natural drug discovery. She is highly skilled in pharmacological testing, utilizing a range of in-vitro and in-vivo models to assess the therapeutic efficacy of plant-based extracts. In addition to her experimental capabilities, Sutha has expertise in analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry, which she has used to identify and quantify bioactive compounds in complex matrices. Her background in biotechnology provides her with a solid understanding of biochemical assays, including enzyme inhibition and receptor binding assays. Furthermore, Sutha has honed her skills in data analysis and interpretation, often using sophisticated statistical tools to evaluate research results. Her ability to combine these skills allows her to contribute to cutting-edge research in drug discovery, particularly in exploring new therapeutic agents derived from natural sources.

Research Interests

Sutha Devaraj’s research interests lie at the intersection of pharmacology, drug discovery, and natural products. She is particularly focused on the exploration of plant-based bioactive compounds and their potential applications in pharmaceutical development. Her Ph.D. research on Strobilanthes crispus exemplifies her dedication to the discovery of new therapeutic agents from natural resources. Sutha is passionate about investigating the hepatoprotective and anticancer properties of various plant species, particularly those indigenous to Southeast Asia. She is also interested in the mechanisms of action of these compounds, aiming to elucidate how they interact with biological systems to exert therapeutic effects. In addition to pharmacological studies, Sutha is keen on formulation development, specifically in optimizing methods for the preparation and stabilization of bioactive extracts. Her future research endeavors include furthering the development of natural-based drugs with fewer side effects compared to conventional synthetic drugs, contributing to a more sustainable and effective approach in pharmaceutical therapy.

Awards and Honors

Sutha Devaraj’s career has been marked by notable recognition for her academic and research contributions. She was awarded a PhD Fellowship by Universiti Sains Malaysia (USM), providing her with the opportunity to carry out high-impact research in the field of pharmaceutical sciences. Additionally, her M.Sc. research on Curcuma xanthorrhiza earned her accolades for its significance in hepatoprotective studies. Sutha’s ability to combine scientific rigor with practical applications has led to her work being published in well-respected, peer-reviewed journals. Her academic excellence and contributions to the field have earned her membership in several prestigious academic organizations and editorial positions in prominent journals related to pharmacology and drug development. Her work continues to be recognized by the academic community, highlighting her as an emerging leader in her field of expertise.

Conclusion

In conclusion, Sutha Devaraj is an accomplished researcher with a strong academic background and expertise in pharmacology and drug discovery. Her dedication to advancing natural product research has led to valuable contributions in the areas of bioactive compound isolation and pharmacological evaluation. Sutha’s research skills, which include advanced analytical techniques and experimental methodologies, equip her to make meaningful advances in the development of therapeutic agents. Her research interests reflect a deep commitment to exploring sustainable and effective natural-based drugs, particularly those with hepatoprotective and anticancer properties. With a growing reputation in the field, Sutha’s work continues to inspire innovation in the pharmaceutical sciences, and her achievements and contributions make her a prominent figure in the ongoing search for new, safer therapeutic options.

Publications Top Notes

1. Evaluation of the Antinociceptive Activity and Acute Oral Toxicity of Standardized Ethanolic Extract of the Rhizome of Curcuma xanthorrhiza Roxb

  • Authors: S. Devaraj, A.S. Esfahani, S. Ismail, S. Ramanathan, M.F. Yam

  • Journal: Molecules, 15(4), 2925–2934

  • Year: 2010

  • Citations: 97

2. Investigation of Antioxidant and Hepatoprotective Activity of Standardized Curcuma xanthorrhiza Rhizome in Carbon Tetrachloride‐Induced Hepatic Damaged Rats

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, M.F. Yam

  • Journal: The Scientific World Journal, 2014(1), 353128

  • Year: 2014

  • Citations: 75

3. Evaluation of the Hepatoprotective Activity of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, S. Marimuthu, Y.M. Fei

  • Journal: Journal of Medicinal Plants Research, 4(23), 2512–2517

  • Year: 2010

  • Citations: 53

4. Anti-Tumor Action, Clinical Biochemistry Profile and Phytochemical Constituents of a Pharmacologically Active Fraction of S. crispus in NMU-Induced Rat Model

  • Authors: N.S. Yaacob, H.M. Yankuzo, S. Devaraj, J.K.M. Wong, C.S. Lai

  • Journal: PLoS One, 10(5), e0126426

  • Year: 2015

  • Citations: 41

5. A Study on the Hepatoprotective Effect of Andrographis paniculata (Burm. F) Nees on Mice

  • Author: D. Sutha

  • Journal: Journal of Phytology, 2(11)

  • Year: 2010

  • Citations: 35

6. In Vivo Toxicological Investigations of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb. Rhizome

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, M. FeiYam

  • Journal: Journal of Natural Products and Plant Resources, 3(1), 67–73

  • Year: 2013

  • Citations: 28

7. Explorations of CRISPR/Cas9 for Improving the Long-Term Efficacy of Universal CAR-T Cells in Tumor Immunotherapy

  • Authors: M. Naeem, A. Hazafa, N. Bano, R. Ali, M. Farooq, S.I. Abd Razak, T.Y. Lee, et al.

  • Journal: Life Sciences, 316, 121409

  • Year: 2023

  • Citations: 23

8. Phytochemical, Antioxidant, Antipyretic and Anti-inflammatory Activities of Aqueous-Methanolic Leaf Extract of Mangifera indica

  • Authors: Q.U. Ain, M.O. Iqbal, I.A. Khan, N. Bano, M. Naeem, M.I. Jamaludin, S. Devaraj

  • Journal: American Journal of Translational Research, 15(7), 4533

  • Year: 2023

  • Citations: 15

9. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients

  • Authors: M. Naeem, N. Bano, S. Manzoor, A. Ahmad, N. Munawar, S.I.A. Razak, T.Y. Lee, et al.

  • Journal: Biomolecules, 13(1), 99

  • Year: 2023

  • Citations: 10

10. Innovative Aspects and Applications of Single Cell Technology for Different Diseases

  • Authors: A. Ali, S. Manzoor, T. Ali, M. Asim, G. Muhammad, A. Ahmad, M.I. Jamaludin, et al.

  • Journal: American Journal of Cancer Research, 14(8), 4028

  • Year: 2024

  • Citations: 1

11. Understanding the Role of Pharmacology and Toxicology in the Research, Development, and Innovation Process by Analyzing the Drug Development Process

  • Authors: L. Waheed, I. Ur Rehman, S. Devaraj, F.H.G.Q. Al-Amier, P. Jativa, G. Naz, et al.

  • Journal: Journal of Pharmaceutical Negative Results, Vol. 14

  • Year: 2023

  • Citations: 1

Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Associate Professor of Pharmacognosy from Deraya university, Egypt

Dr. Eman Maher Zahran is a distinguished academic and researcher in the field of pharmacognosy, currently serving as an Associate Professor at Deraya University’s Faculty of Pharmacy. With a career rooted in natural product research, her work spans the morphological study of medicinal plants to the biological activities of phytoconstituents. A Ph.D. graduate from Minia University, she has demonstrated unwavering commitment to academic excellence, scientific innovation, and student mentorship. Her research integrates traditional knowledge with advanced technologies such as metabolomic profiling, ESI-HR-MS analysis, and molecular docking. Dr. Zahran has authored over 25 impactful peer-reviewed articles and delivered talks at key international and national pharmaceutical conferences. In addition to her scholarly contributions, she is actively involved in student-centered initiatives, scientific committees, and governmental outreach programs. Her editorial and peer-review work across several international journals further amplifies her impact within the global scientific community. A strong advocate for female leadership in science, she completed the prestigious “The Woman Leads” program at Egypt’s National Training Academy. Dr. Zahran’s blend of academic excellence, innovative research, leadership in community engagement, and dedication to advancing pharmacognosy education positions her as a leading figure in Egypt’s pharmaceutical sciences landscape.

Professional Profile

Education

Dr. Eman Maher Zahran’s educational journey is deeply rooted in Minia University, where she pursued her undergraduate, master’s, and doctoral degrees in Pharmaceutical Sciences with a specialization in Pharmacognosy. She completed her B.Sc. in Pharmaceutical Sciences in 2006 with a cumulative grade of “Very Good.” Her keen interest in medicinal plants and natural product research led her to undertake pre-master courses in 2007, which served as the foundation for her M.Sc. that spanned from 2007 to 2013. Her master’s research involved the detailed phytochemical investigation of plant constituents and their pharmacological evaluation. From 2016 to 2020, she pursued her Ph.D. at the Faculty of Pharmacy, Minia University, where she delved into advanced areas such as metabolomics, molecular docking, and structure elucidation of phytoconstituents. Her doctoral work not only reflected technical expertise but also interdisciplinary collaboration. During this academic trajectory, she also completed specialized training programs and participated in scientific workshops that refined her methodological capabilities. The strength of her education lies in its comprehensive nature, encompassing foundational knowledge, research techniques, and a critical understanding of the pharmacological potential of natural compounds, all of which have laid the groundwork for her ongoing contributions to pharmaceutical research and academia.

Professional Experience

Dr. Zahran’s professional trajectory reflects a steady and strategic ascent through the academic ranks of pharmacognosy. She began her journey as a community pharmacist, transitioning into academia in 2008 as a postgraduate researcher and then as a teaching assistant. Between 2010 and 2012, she served as a grant teaching assistant for Clinical Pharmacy students. From 2016 to 2020, she was appointed Associate Lecturer at the Faculty of Pharmacy, Minia University. In 2020, she was promoted to Assistant Professor, where she continued to lead educational initiatives, mentor students, and develop curricula. As of March 2025, she holds the rank of Associate Professor at Deraya University. Dr. Zahran has also been deeply involved in co-curricular activities, supervising multiple student-led initiatives such as “Hayah,” a student entity focused on scientific and community outreach. She has contributed to post-graduate course development and served on Deraya’s Quality Assurance and Accreditation Unit. Her participation in national-level training programs like “The Woman Leads” demonstrates her leadership and civic engagement. With over 15 years of diverse experience spanning pharmacy practice, teaching, and research, Dr. Zahran has emerged as a dynamic academic professional, recognized for her commitment to excellence, innovation, and interdisciplinary collaboration.

Research Interests

Dr. Zahran’s research interests center on pharmacognosy and natural product chemistry, with a strong emphasis on isolating, identifying, and evaluating bioactive phytoconstituents derived from medicinal plants and marine algae. Her work integrates classical botanical techniques with cutting-edge technologies like ESI-HR-MS analysis and molecular docking. A unique aspect of her research involves the application of network pharmacology to uncover the multi-target mechanisms of natural compounds, especially in treating complex disorders like ADHD and osteoarthritis. Her contributions extend to investigating the wound healing, antifungal, antiplasmodial, and anti-inflammatory properties of various natural substances. Recently, she has delved into combining natural phytochemicals with stem cell therapies to enhance regenerative medicine applications. Additionally, Dr. Zahran’s studies examine the environmental and biochemical effects of phytoconstituents using in vitro, in vivo, and in silico models. This holistic and multidisciplinary approach allows her to bridge the gap between traditional herbal medicine and contemporary pharmacological science. Her interest in neuropsychiatric disorders also reflects a forward-thinking orientation, exploring novel therapeutic avenues. Through her robust pipeline of projects and publications, she continues to identify plant-based compounds with the potential to be developed into pharmaceutical agents, contributing significantly to both academic knowledge and practical healthcare innovation.

Research Skills

Dr. Eman Maher Zahran is equipped with an extensive set of research skills that make her a leading expert in pharmacognosy and natural product research. She is proficient in the morphological and micromorphological analysis of medicinal plants and marine algae, with deep expertise in isolation and structure elucidation techniques for phytochemicals. Her methodological proficiency spans thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and advanced mass spectrometric techniques, including ESI-HR-MS. Furthermore, she demonstrates high competence in molecular docking, network pharmacology, and in silico ADME studies, which she integrates seamlessly into phytochemical investigations. Dr. Zahran is also skilled in conducting both in vitro and in vivo biological activity assessments, exploring pharmacodynamics and pharmacokinetics of bioactive compounds. Her research frequently employs interdisciplinary approaches, such as combining plant extracts with mesenchymal stem cells in regenerative medicine models. Additionally, she is adept in scientific writing and publishing, having authored numerous high-impact papers in Scopus-indexed and Web of Science journals. Her peer-review activities and editorial board membership further reflect her critical appraisal capabilities. Collectively, her skills not only underscore her technical competence but also her innovative spirit and dedication to producing translational research that advances healthcare through natural product pharmacology.

Awards and Honors

Dr. Eman Maher Zahran has garnered significant recognition for her academic achievements, both within her institution and the broader scientific community. She was honored by Deraya University for her outstanding academic contributions from 2020 onward, a period during which she published prolifically and advanced numerous research projects. Her active role in student development and community outreach, particularly through her supervision of the “Hayah” entity and ADHD-focused conferences, highlights her multifaceted impact. In 2023, she was selected to join the second cohort of the Egyptian National Training Academy’s “The Woman Leads” program, which is designed to empower and equip promising female leaders in science and education. She serves as an editorial board member and peer reviewer for multiple prestigious journals, including the Journal of Pharmaceutical Chemistry & Chemical Science, Octahedron Drug Research, and journals by the Royal Society of Chemistry. Furthermore, her selection to the scientific committee of international congresses on nanoscience and pharmacology reflects her expertise and respected standing in the academic community. These honors not only affirm her scientific merit but also her leadership, dedication to knowledge dissemination, and her influential role in shaping the future of pharmacognosy in Egypt and beyond.

Conclusion

Dr. Eman Maher Zahran exemplifies the qualities of a dedicated academic, an innovative researcher, and an inspiring mentor. Her career is marked by a relentless pursuit of excellence, from foundational studies in pharmaceutical sciences to cutting-edge research in natural product pharmacology. Her interdisciplinary focus—combining phytochemistry, molecular modeling, and regenerative medicine—demonstrates her commitment to translating traditional medicinal knowledge into therapeutic breakthroughs. Dr. Zahran’s engagement with students, leadership in research committees, and active role in scientific communication reflect her holistic academic persona. Her prolific publication record, participation in international conferences, and collaborations underscore her relevance on both national and global levels. Equally commendable is her devotion to community-based initiatives, particularly in raising awareness and support for neuropsychiatric conditions like ADHD. Her recognition through institutional awards and national leadership programs stands as a testament to her impact. As she continues to expand her research footprint and inspire the next generation of scientists, Dr. Zahran remains a vital force in the advancement of pharmacognosy and pharmaceutical sciences. Her contributions resonate far beyond the laboratory and classroom, positioning her as a role model and a key influencer in the evolving landscape of academic research and community health promotion.

Publications Top Notes

  • Title: Diversity, phytochemical and medicinal potential of the genus Ocimum L. (Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, HE Khalil, SY Desoukey, MA Fouad, …
    Year: 2020
    Citations: 86

  • Title: Bioactivity potential of marine natural products from scleractinia-associated microbes and in silico anti-SARS-COV-2 evaluation
    Authors: EM Zahran, A Albohy, A Khalil, AH Ibrahim, HA Ahmed, EM El-Hossary, …
    Year: 2020
    Citations: 41

  • Title: Antioxidant and wound healing potential of Vitis vinifera seeds supported by phytochemical characterization and docking studies
    Authors: T Al-Warhi, EM Zahran, S Selim, MM Al-Sanea, MM Ghoneim, SA Maher, …
    Year: 2022
    Citations: 36

  • Title: Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation
    Authors: A Albohy, EM Zahran, UR Abdelmohsen, MA Salem, T Al-Warhi, …
    Year: 2022
    Citations: 29

  • Title: Antiulcer potential and molecular docking of flavonoids from Ocimum forskolei Benth., family Lamiaceae
    Authors: EM Zahran, UR Abdelmohsen, AS Hussein, MA Salem, HE Khalil, …
    Year: 2021
    Citations: 27

  • Title: Scabicidal potential of coconut seed extract in rabbits via downregulating inflammatory/immune cross talk: A comprehensive phytochemical/GC-MS and in silico proof
    Authors: EM Zahran, NMR Abdel-Maqsoud, OY Tammam, IM Abdel-Rahman, …
    Year: 2022
    Citations: 23

  • Title: New Acaciin-loaded self-assembled nanofibers as MPro inhibitors against BCV as a surrogate model for SARS-CoV-2
    Authors: SA Mohamad, EM Zahran, MR Abdel Fadeel, A Albohy, MA Safwat
    Year: 2021
    Citations: 23

  • Title: New halogenated compounds from Halimeda macroloba seaweed with potential inhibitory activity against malaria
    Authors: AH Elmaidomy, EM Zahran, R Soltane, A Alasiri, H Saber, CJ Ngwa, …
    Year: 2022
    Citations: 22

  • Title: Metabolic profiling, histopathological anti-ulcer study, molecular docking and molecular dynamics of ursolic acid isolated from Ocimum forskolei Benth. (family Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, AT Ayoub, MA Salem, HE Khalil, …
    Year: 2020
    Citations: 21

  • Title: Cytotoxic and anti-diabetic potential, metabolic profiling and in silico studies of Syzygium cumini (L.) Skeels belonging to family Myrtaceae
    Authors: SS Eldin Elhawary, AE Elmotayam, D Alsayed, EM Zahran, MA Fouad, …
    Year: 2022
    Citations: 11

Serkan Yigitkan | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Assist. Prof. Dr. Serkan Yigitkan | Pharmaceutical Science | Best Researcher Award

Dicle University, Turkey

Dr. Serkan Yiğitkan is a distinguished pharmacognosist affiliated with Dicle University’s Institute of Health Sciences in Diyarbakır, Turkey. His academic journey is marked by a profound dedication to the study of medicinal plants and their applications in healthcare. With a robust portfolio of 18 publications and a significant number of citations, Dr. Yiğitkan has established himself as a leading figure in his field. His research primarily focuses on the pharmacological properties of natural products, aiming to bridge the gap between traditional herbal remedies and modern medicine. Through his work, he seeks to validate and harness the therapeutic potentials of phytochemicals, contributing to the development of novel treatments for various ailments.

Professional Profile

Education

Dr. Yiğitkan completed his doctoral studies in pharmacognosy at Dicle University, where he delved into the chemical and biological properties of medicinal plants. His education provided a solid foundation in understanding the complexities of plant-based compounds and their interactions within biological systems. This academic background has been instrumental in shaping his research trajectory, allowing him to explore the vast potential of phytochemicals in therapeutic applications. His commitment to continuous learning and research is evident in his contributions to the scientific community, particularly in the realm of natural product pharmacology.

Professional Experience

Throughout his career, Dr. Yiğitkan has been actively involved in various research projects and academic collaborations. His role at Dicle University encompasses both teaching and research, where he mentors students and leads studies on the pharmacological effects of medicinal plants. His professional journey is characterized by a dedication to advancing the understanding of natural products and their potential therapeutic benefits. Through his involvement in numerous studies and publications, he has contributed significantly to the field of pharmacognosy, particularly in exploring the antimicrobial and antioxidant properties of plant extracts.

Research Interests

Dr. Yiğitkan’s research interests are centered around the pharmacological evaluation of medicinal plants, with a particular focus on their antimicrobial and antioxidant properties. He is keenly interested in identifying bioactive compounds that can serve as potential therapeutic agents. His work often involves the extraction and characterization of phytochemicals, aiming to discover novel compounds with significant health benefits. By investigating the traditional uses of plants and validating their efficacy through scientific methods, he contributes to the integration of herbal medicine into modern therapeutic practices.

Research Skills

Dr. Yiğitkan possesses a diverse set of research skills, including expertise in chromatographic techniques, bioassay-guided fractionation, and the evaluation of biological activities of natural products. His proficiency in these methodologies enables him to isolate and identify active compounds from complex plant matrices effectively. Additionally, his skills in designing and conducting experiments related to antimicrobial and antioxidant assays have been pivotal in advancing his research objectives. His methodological approach ensures the reliability and reproducibility of his findings, contributing to the broader scientific understanding of medicinal plants.

Awards and Honors

While specific awards and honors are not detailed in the available information, Dr. Yiğitkan’s contributions to the field of pharmacognosy are evident through his extensive publication record and the impact of his research. His work has garnered attention within the scientific community, reflecting his commitment to advancing knowledge in natural product research. The recognition of his studies by peers and the inclusion of his research in reputable journals underscore his standing as a respected scientist in his field.

Conclusion

Dr. Serkan Yiğitkan’s dedication to exploring the medicinal properties of plants has significantly enriched the field of pharmacognosy. His research endeavors have not only advanced scientific understanding but also paved the way for the development of novel therapeutic agents derived from natural sources. Through his meticulous studies and commitment to integrating traditional knowledge with modern science, Dr. Yiğitkan exemplifies the vital role of researchers in bridging cultural heritage and contemporary medicine. His ongoing efforts continue to inspire and contribute to the global appreciation of plant-based therapeutics.

Publications Top Notes

  1. Title: Assessment of the Anti-Acne Properties of Some Medicinal Plants and Development of an Herbal Anti-Acne Formulation
    Authors: F. Sezer Senol Deniz, Ozlem Oyardı, Cagla Bozkurt Guzel, Tahir Emre Yalcın, Serkan Yiğitkan, Yuksel Kan, Nurver Ulger Toprak, Ilkay Erdogan Orhan
    Year: 2025

  2. Title: LC-MS/MS Analysis and Biological Activities of Different Parts of Ziziphora capitate L.
    Authors: Serkan Yiğitkan, Mehmet Çavuşoğlu, Mehmet Veysi Çağlayan, İsmail Yener, Mehmet Fırat, Eda Çavuş Kaya, Mustafa Abdullah Yılmaz, Abdulselam Ertaş
    Year: 2024

  3. Title: Ziziphora clinopodioides Lam. Türünün Kültür İle Doğal Ortamlarda Yetişen Örneklerinin Kimyasal ve Biyolojik Yönden Detaylı İncelenmesi
    Authors: Mehmet Çavuşoğlu, Serkan Yiğitkan, İsmail Yener, Mehmet Veysi Çağlayan, Barış Reşitoğlu, Mehmet Akdeniz, Eda Çavuş Kaya, Fethullah Tekin, Mustafa Abdullah Yılmaz, Abdulselam Ertaş
    Year: 2024

  4. Title: A Comprehensive Study on Chemical and Biological Investigation of Thymus Brachychilus Jalas: A Rich Source of Ursolic and Oleanolic Acids
    Authors: Mehmet Akdeniz, Serkan Yiğitkan, Mustafa Abdullah Yılmaz, İsmail Yener, Elif Varhan Oral, Mehmet Fırat, Ilkay Erdogan Orhan, Ufuk Kolak, Abdulselam Ertaş
    Year: 2024

  5. Title: Essential Oil Contents and Biological Activities of Thymus Canoviridis Jalas and Thymus Sipyleus Boiss.
    Authors: Serkan Yiğitkan, Mehmet Fırat
    Year: 2024

  6. Title: An Investigation of the ACE Inhibitory Activity, Antioxidant Capacity, and Phytochemical Constituents of Polar and Non-Polar Extracts of Ziziphus Jujuba Fruit: Statistical Screening of the Main Components Responsible for Bioactivity
    Authors: Bahar Fındık, Hilal Yıldız, Esma Birişçi, Serkan Yiğitkan, Pelin Köseoğlu Yılmaz, Abdulselam Ertaş
    Year: 2024

  7. Title: Comprehensive Study of Chemical Composition and Biological Activity of Thymus pubescens Boiss. et Kotschy ex Čelak.
    Authors: Serkan Yiğitkan, Mehmet Akdeniz, İsmail Yener, Zeki Seker, Mustafa Abdullah Yılmaz, Mehmet Fırat, Deniz Evrim Kavak, Pelin Yılmaz Köseoğlu, Abdulselam Ertaş, Ufuk Kolak
    Year: 2022

Mycal Dutta | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Mycal Dutta | Pharmaceutical Science | Best Researcher Award

Associate Professor at University of Science and Technology (USTC), Bangladesh

Dr. Mycal Dutta is an accomplished Associate Professor in the Department of Pharmacy at the University of Science and Technology Chittagong (USTC), Bangladesh. With nearly fourteen years of experience in academia, research, and professional practice, he has made significant contributions to pharmaceutical sciences. Dr. Dutta earned his Ph.D. in Pharmacy from Jahangirnagar University, Dhaka, in December 2022. His expertise spans pharmaceutical technology, microbiology, and clinical pharmacy. He has published 36 research papers in national and international journals, focusing on bioactive phytochemicals, drug formulation, and pharmacological investigations. As a registered “A” Grade Pharmacist, he actively contributes to professional training and advisory committees. His research interests include the isolation of medicinal plant compounds, computational drug design, and molecular docking studies. Dr. Dutta has received several research grants, including government-funded projects on ethnomedicinal plants. Apart from his academic roles, he has been involved in organizing scientific conferences and student welfare activities. His commitment to teaching, research, and pharmaceutical advancements has made him a distinguished figure in the field.

Professional Profile

Education

Dr. Mycal Dutta has a strong academic background in pharmacy. He obtained his Ph.D. in Pharmacy from Jahangirnagar University, Dhaka, in December 2022. Prior to this, he completed his Master of Pharmacy (Thesis) degree from Southern University, Bangladesh, in 2011, achieving a CGPA of 3.6 on a 4.0 scale. He earned his Bachelor of Pharmacy (Hons.) degree from the University of Science and Technology Chittagong (USTC) in 2009, graduating with First Class honors. His foundational education includes a Higher Secondary Certificate (HSC) from Govt. Hazi Muhammad Mohsin College, Chittagong, with a GPA of 4.70 out of 5.00 in 2004, and a Secondary School Certificate (SSC) from Collegiate School, Chittagong, with a GPA of 4.38 out of 5.00 in 2002. His educational journey reflects his dedication to academic excellence and pharmaceutical sciences.

Professional Experience

Dr. Mycal Dutta has extensive teaching and research experience in the field of pharmacy. He has been serving as an Associate Professor at the University of Science and Technology Chittagong (USTC) since July 2023. Previously, he worked as an Assistant Professor at BGC Trust University Bangladesh for nearly eight years (2015–2023) and as a Lecturer at the same institution for almost five years (2011–2015). In addition to his teaching roles, he has contributed significantly to academic administration, including serving as an advisor in the Student Welfare Advisory Committee at USTC and as Chief Advisor of the Career Development and Placement Club at BGC Trust University. His professional contributions extend to chairing scientific and publication committees for national conferences and participating in examination committees. His vast experience demonstrates his dedication to pharmacy education and academic leadership.

Research Interests

Dr. Mycal Dutta’s research interests focus on pharmacological and phytochemical investigations of medicinal plants. His work involves compound isolation using techniques such as Nuclear Magnetic Resonance (NMR) and Gas Chromatography-Mass Spectrometry (GC-MS). He is particularly interested in computational drug discovery, molecular docking, Quantitative Structure-Activity Relationship (QSAR) modeling, and ADME/T property analysis of natural compounds. His research aims to bridge wet lab and dry lab approaches to develop therapeutic solutions from natural products. He also explores antimicrobial studies, aseptic techniques, bacterial staining, and in vitro and in vivo pharmacological investigations. His research contributions significantly advance the understanding of bioactive phytochemicals and their therapeutic potential.

Research Skills

Dr. Mycal Dutta possesses a diverse range of research skills, including microbiological techniques such as aseptic handling, bacterial staining, and antimicrobial sensitivity testing. He is proficient in computational drug design, protein modeling, and molecular simulations. His technical expertise extends to animal research, including transgenic and knockout mouse models. He is skilled in using various molecular modeling and Computer-Aided Drug Design (CADD) software. Additionally, he has extensive experience with statistical analysis tools such as GraphPad Prism and SPSS. His proficiency in these areas enables him to conduct high-quality research and mentor students in advanced pharmaceutical investigations.

Awards and Honors

Dr. Mycal Dutta has received several prestigious research grants and recognitions. He was awarded the R&D Grant for Science and Technology (2022–2023) from the Ministry of Science and Technology, Bangladesh, for his research on bioactive phytochemicals. Additionally, he secured a research grant from BGC Trust University Bangladesh in 2017 to support his Ph.D. research. His contributions to pharmaceutical research have been acknowledged through numerous publications in high-impact journals. He has also played a key role in organizing national conferences and scientific symposiums. His commitment to research and academia has earned him a strong reputation in the field of pharmaceutical sciences.

Conclusion

Dr. Mycal Dutta is a dedicated researcher, educator, and pharmaceutical scientist committed to advancing pharmaceutical education and research. With nearly fourteen years of experience, he has made remarkable contributions to pharmacology, phytochemistry, and drug discovery. His extensive research on medicinal plants and computational drug design has positioned him as a leading expert in the field. His passion for teaching, mentoring students, and conducting groundbreaking research continues to impact the pharmaceutical sciences significantly. Through his academic leadership, professional affiliations, and research initiatives, he remains at the forefront of pharmaceutical innovation and education.

Publications Top Notes

  1. Yusuf, A., Shaikat, M. A., Bhuiya, M. A. M., Dutta, M., Nath, A. K., & Dash, P. R. (2023). Utilizing the Medicinal Properties of Delonix regia for Diseases and Beyond: A Review of its Phytochemistry and Pharmacology. Tropical Journal of Natural Product Research, 7(12), 5355–5365. DOI: 10.26538/tjnpr/v7i12.2

  2. Malini, S., Raj, K., Madhumathy, S., El-Hady, K. M., Islam, S., & Dutta, M. (2022). Bioinspired Advances in Nanomaterials for Sustainable Agriculture. Journal of Nanomaterials, 2022, Article ID 8926133. DOI: 10.1155/2022/8926133

  3. Vaidya, S., Jeengar, M., Wadaan, M. A., Mahboob, S., Kumar, P., Reece, L. M., Bathula, S. R., & Dutta, M. (2022). Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID 9231641. DOI: 10.1155/2022/9231641

  4. Jadhav, V., Bhagare, A., Wahab, S., Lokhande, D., Vaidya, C., Dhayagude, A., Khalid, M., Aher, J., Mezni, A., & Dutta, M. (2022). Green Synthesized Calcium Oxide Nanoparticles (CaO NPs) Using Leaves Aqueous Extract of Moringa oleifera and Evaluation of Their Antibacterial Activities. Journal of Nanomaterials, 2022, Article ID 9047507. DOI: 10.1155/2022/9047507

  5. Jadhav, V., Bhagare, A., Ali, I. H., Dhayagude, A., Lokhande, D., Aher, J., Jameel, M., & Dutta, M. (2022). Role of Moringa oleifera on Green Synthesis of Metal/Metal Oxide Nanomaterials. Journal of Nanomaterials, 2022, Article ID 2147393. DOI: 10.1155/2022/2147393

  6. Alharthy, S. A., Shams Tabrez, S., Ahmed A. Mirza, A. A., Torki A. Zughaibi, Firoz, C. K., & Dutta, M. (2022). Sugiol Suppresses the Proliferation of Human U87 Glioma Cells via Induction of Apoptosis and Cell Cycle Arrest. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID 7658899. DOI: 10.1155/2022/7658899

  7. Dutta, M., Akter, T., Nezam, M., Paul, A., & Rana, M. S. (2022). In silico Molecular Docking and ADME/T Analysis of Selected Bioactive Compounds from Leucas zeylanica against Breast Cancer. BGC Trust University Journal, 6, 51–66.

  8. Dutta, M., Tareq, A. M., Rakib, A., Mahmud, S., Sami, S. A., Mallick, J., Islam, M. N., Majumder, M., Uddin, M. Z., Alsubaie, A., & Almalki, A. S. (2021). Phytochemicals from Leucas zeylanica Targeting Main Protease of SARS-CoV-2: Chemical Profiles, Molecular Docking, and Molecular Dynamics Simulations. Biology, 10(8), 789. DOI: 10.3390/biology10080789

  9. Dutta, M., Nezam, M., Chowdhury, S., Rakib, A., Paul, A., Sami, S. A., Uddin, M. Z., Rana, M. S., Hossain, S., Effendi, Y., Idroes, R., Tallei, T. E., Alqahtani, A. M., & Emran, T. B. (2021). Appraisals of the Bangladeshi Medicinal Plant Calotropis gigantea Used by Folk Medicine Practitioners in the Management of COVID-19: A Biochemical and Computational Approach. Frontiers in Molecular Biosciences, 8, 625391. DOI: 10.3389/fmolb.2021.625391

  10. Rakib, A., Paul, A., Ahmed, S., Chy, M. N. U., Baral, S. K., Majumder, M., Tareq, A. T., Amin, M. N., Shahriar, A., Uddin, M. Z., Dutta, M., Tallei, T. E., Emran, T. B., & Simal-Gandara, J. (2020). Biochemical and Computational Approach of Phytocompounds from Tinospora crispa in the Management of COVID-19: Molecules; 25(17): E3936. DOI: 10.3390/molecules25173936

Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1

 

 

 

Moein Masjedi | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Moein Masjedi | Pharmacology | Best Researcher Award

Moein Masjedi, DarooSazan Sorena Exir Pharmaceutical Company, Iran.

Moein Masjedi is a dedicated researcher in the field of pharmacology, recognized for his innovative contributions to drug development and therapeutic strategies. With a strong academic background and a commitment to advancing scientific knowledge, he has published numerous influential papers that address critical challenges in the field. Awarded the Best Researcher Award for his outstanding research impact, Moein continues to inspire peers and students through his passion for improving health outcomes and enhancing patient care.

Profile:

Education

Moein Masjedi earned his Doctor of Pharmacy degree from Shiraz University of Medical Sciences in Shiraz, Fars, Iran, where he completed his thesis on the drug utilization evaluation of captopril in two coronary care units at Namazi Hospital, achieving a GPA of 15.64 out of 20. He then pursued a Ph.D. in Pharmaceutics at the same institution, focusing on the nose-to-brain delivery of Sumatriptan using chitosan nanoparticles and nanostructured lipid carriers (NLCs), and graduated with a GPA of 17.83 out of 20.

 

Skills 

Moein Masjedi possesses a diverse skill set that enhances his effectiveness as a researcher and collaborator. He excels in strong and collaborative communication, fostering teamwork and idea exchange. His creativity in problem-solving and critical thinking enables him to tackle complex challenges in pharmacology. Demonstrating leadership qualities, he effectively manages projects while prioritizing time management to meet deadlines. Additionally, he is skilled in structural scientific writing and proofreading, ensuring clarity and precision in his research publications. Beyond academia, Moein has a passion for art interpretation and enjoys swimming and yoga, which contribute to his overall well-being and work-life balance.

Areas of Interest:

Moein Masjedi’s research interests focus on innovative drug delivery systems and formulation design. He is particularly passionate about nanoparticulate drug delivery and the optimization of formulations for pulmonary, ocular, topical, and transdermal applications. His work includes designing novel drug delivery systems targeting specific sites such as the pulmonary system, colon, brain, and hair follicles. He explores the use of nanovesicles, lipid, and polymeric nanoparticles for both therapeutic and cosmetic applications. Additionally, Moein is interested in D-optimal optimization of aesthetic formulations and the development of stimuli-responsive or smart polymers for drug delivery. He employs Design of Experiments (DoE) methodologies to optimize formulations and is also engaged in the innovative 3D printing of pharmaceutical dosage forms, aiming to advance the field of pharmaceutics.

Publication Top Notes

  1. Masjedi, M., Izadi, Y., Montahaei, T., Mohammadi, R., Helforoush, M. A., & Rohani Rad, K. (2024). An illustrated review on herbal medicine used for the treatment of female infertility. European Journal of Obstetrics and Gynecology and Reproductive Biology, 0(0).
  2. Dahri, M., Beheshtizadeh, N., Seyedpour, N., Nakhostin-Ansari, A., Aghajani, F., Seyedpour, S., Masjedi, M., Farjadian, F., Maleki, R., & Adibkia, K. (2023). Biomaterial-based delivery platforms for transdermal immunotherapy. Biomedicine & Pharmacotherapy, 165, 115048.
  3. Rezaie, F., Farshbaf, M., Dahri, M., Masjedi, M., Maleki, R., Amini, F., Wirth, J., Moharamzadeh, K., Weber, F. E., & Tayebi, L. (2023). 3D printing of dental prostheses: Current and emerging applications. Journal of Composites Science, 7(2), 80.
  4. Masjedi, M., Montahaei, T., Sharafi, Z., & Jalali, A. (2022). Pulmonary vaccine delivery: An emerging strategy for vaccination and immunotherapy. Journal of Drug Delivery Science and Technology, 103184.
  5. Masjedi, M., & Solhjoo, A. (2022). Does trigonelline help skin tone? Molecular docking studies of trigonelline on the human tyrosinase, formulation, optimization and characterization of an emulgel containing Trigonella foenum‐graecum L. fenugreek standardized hydroalcoholic extract. Journal of Cosmetic Dermatology.
  6. Masjedi, M., & Namazi, S. (2020). Drug utilization evaluation (DUE) of captopril in two coronary care units (CCU) of Namazi Hospital, Shiraz, Iran.
  7. Masjedi, M., & Montahaei, T. (2020). An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug delivery: Fabrication, characterization, pharmaceutical, and cosmetic applications. Journal of Drug Delivery Science and Technology, 102234.
  8. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi-Samani, S. (2020). Brain targeted delivery of sumatriptan succinate loaded chitosan nanoparticles: Preparation, in vitro characterization, and (neuro-) pharmacokinetic evaluations. Journal of Drug Delivery Science and Technology, 102179.
  9. Ziaei, A., Davoodian, P., Dadvand, H., Safa, O., Hassanipour, S., Omidi, M., Masjedi, M., Mahmoudikia, F., Rafiee, B., & Fathalipour, M. (2020). Evaluation of the efficacy and safety of melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), 1-3.
  10. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi‐Samani, S. (2020). Nose‐to‐brain delivery of sumatriptan‐loaded nanostructured lipid carriers: Preparation, optimization, characterization, and pharmacokinetic evaluation. Journal of Pharmacy and Pharmacology, 72(10), 1341-1351.

Sujatha Kuppusamy | Microbiology | Best Researcher Award

Posted on by ScienceFather

Sujatha Kuppusamy | Microbiology | Best Researcher Award

Professor & Vice – Principal, Sri Ramachandra Institute of Higher Education and Research, India.

Dr. K. Sujatha Kuppusamy is a renowned Professor in the Department of Pharmaceutical Chemistry at Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU) in Chennai, India. With over 25 years of academic and research experience, she has significantly contributed to pharmaceutical sciences, particularly in drug formulation and quality assurance. Dr. Sujatha holds a Ph.D. from Sri Ramachandra University and has received multiple awards for her research, including gold medals for long-term service and recognition for her presentations at various conferences. Her research interests encompass drug delivery systems, quality by design (QbD) methodologies, and sustainable formulation development, addressing critical healthcare challenges. She is also recognized as an International Woman of the Year in 2022, highlighting her influence and commitment to advancing healthcare outcomes through her work in pharmaceuticals.

Profile:

Scopus Profile

ORCID

Education

Dr. K. Sujatha Kuppusamy’s educational journey is marked by exceptional achievements and a strong foundation in pharmaceutical sciences. She completed her Ph.D. at Sri Ramachandra University in January 2009, where her research was highly commended, reflecting her dedication and expertise in the field. Prior to her doctoral studies, she earned her Master of Pharmacy (M.Pharm) in Pharmaceutical Chemistry in March 1997 from The T.N. Dr. MGR Medical University, graduating with first-class honors. Dr. Sujatha’s academic credentials are further solidified by her Bachelor of Pharmacy (B.Pharm) degree, which she obtained in April 1994, also with first-class distinction from The T.N. Dr. MGR Medical University. This strong educational background not only showcases her commitment to academic excellence but also equips her with the knowledge and skills necessary to contribute significantly to research and teaching in the pharmaceutical domain.

Professional Experience

Dr. K. Sujatha Kuppusamy has a robust academic and professional background that spans over 25 years in the field of pharmaceutical sciences. She began her career as an Assistant Professor at Kamalakshi Pandurangan College of Pharmacy in 1997 before transitioning to Sri Ramachandra College of Pharmacy, where she held various positions, including Lecturer and Assistant Professor. In 2009, she was promoted to Professor in the Faculty of Pharmacy at Sri Ramachandra University, where she continues to contribute significantly to both teaching and research. Throughout her career, Dr. Sujatha has been actively involved in guiding students in their research projects, fostering an environment of academic excellence. Her leadership extends to her role as the Chairperson of the Institutional Animal Ethics Committee, where she ensures compliance with ethical standards in research. Dr. Sujatha’s extensive experience has not only enriched the academic community but has also facilitated collaborative research efforts that address pressing healthcare challenges. Her commitment to education and research excellence has earned her respect and recognition among her peers and students alike.

Research Interests

Dr. K. Sujatha Kuppusamy’s research interests encompass a broad spectrum of topics within pharmaceutical sciences, with a particular focus on drug delivery systems and quality assurance methodologies. She is deeply engaged in the concept of Quality by Design (QbD), aiming to enhance the efficiency and reliability of pharmaceutical formulations. Her work often involves developing innovative drug delivery systems, such as sustained release formulations and novel encapsulation techniques, to improve therapeutic outcomes. Additionally, Dr. Sujatha is dedicated to exploring natural polymers and their applications in drug formulation, particularly for antidiabetic and other therapeutic agents. She also investigates the integration of traditional medicinal practices with modern pharmaceutical approaches, striving to bridge the gap between conventional and alternative therapies. Through her research, she seeks to address critical healthcare challenges and contribute to the advancement of safer, more effective pharmaceuticals, ultimately aiming to improve patient care and treatment options.

Award and Recognition

Dr. K. Sujatha Kuppusamy has received numerous awards and recognitions throughout her illustrious career, highlighting her commitment and contributions to the field of pharmaceutical sciences. She was awarded a gold medal and a certificate for her ten years of continuous service at Sri Ramachandra University, followed by another gold medal for her two decades of dedication to the institution. Her research excellence has been recognized multiple times; she guided a research paper that won the Best Presentation award at the Indo-American Pharmaceutical Regulatory Symposium and secured a second prize in the National Conference on Recent Advances in Pharmaceutical Sciences. Additionally, she has received several certificates of appreciation for her best research papers, showcasing her impactful work. Dr. Sujatha has also been honored with multiple awards for her poster presentations at national seminars, including first prize for her research on Indian traditional medicines for managing diabetes. Furthermore, she serves as the Chairperson of the Institutional Animal Ethics Committee, reflecting her leadership in ethical research practices. Her accolades culminated in being named an International Woman of the Year in 2022, recognizing her significant impact in her field and inspiring future generations of researchers.

 

Publication Top Notes

      1. QbD-Based Stability-Indicating RP-HPLC Method Development and Validation for the Estimation of Favipiravir—An Eco-Friendly Approach
        Authors: Siri Chandana, M., Sujatha, K., Ajitha, A., Narendra, P., Sonia, K.
        Year: 2024
        Citation: Journal of AOAC International, 107(3), pp. 377–386. 🧪🌱
      2. An Overview of Pharmacological Activities and Beneficial Effects of 3-Hydroxyflavone
        Authors: Ayyanna, C., Kuppusamy, S., Kumar, P.P.
        Year: 2024
        Citation: Macromolecular Symposia, 413(2), 2300078. 📚💊
      3. Analytical Quality by Design-Assisted HPLC Method for Quantification of Canagliflozin and Stability Studies
        Authors: Azhakesan, A., Kuppusamy, S.
        Year: 2023
        Citation: ACS Omega, 8(8), pp. 7407–7414. 🔍📈
      4. Development and Validation of UFLC-MS/MS Analytical Method for the Simultaneous Quantification of Antibiotic Residues in Surface Water, Groundwater, and Pharmaceutical Waste Water Samples from South India
        Authors: Kamatham, S., Seeralan, M., Sekar, U., Kuppusamy, S.
        Year: 2023
        Citation: ACS Omega. 🌊💧
      5. QbD-Based Development and Validation of Novel Stability-Indicating Method for the Assay and Dissolution of Garenoxacin in Garenoxacin Tablets
        Authors: Azhakesan, A., Kuppusamy, S.
        Year: 2022
        Citation: Journal of AOAC International, 105(2), pp. 370–378. 📦💊
      6. Canagliflozin: A review with specific focus on analytical methods in biological matrices and pharmaceuticals
        Authors: Azhakesan, A., Kuppusamy, S.
        Year: 2022
        Citation: Reviews in Analytical Chemistry, 41(1), pp. 287–300. 🧬📖
      7. Formulation and Evaluation of Miglitol Matrix Tablets by Using Hibiscus Rosa Sinensis Leaves Mucilage
        Authors: Deepika, B., Sujatha, K., Thanga Thirupathi, A., Chamundeeswari, D.
        Year: 2021
        Citation: Research Journal of Pharmacy and Technology, 14(1), pp. 245–248. 🌺💊
      8. Bioanalytical Method Development and Validation for Simultaneous Estimation of Nitazoxanide and Ofloxacin in Human Plasma by RP-HPLC
        Authors: Ajitha, A., Abbulu, K., Sujatha, K., Sireesha, P.
        Year: 2020
        Citation: Indian Drugs, 57(10), pp. 47–57. 💉🔬
      9. Bioanalytical Method Development and Validation of Garenoxacin Mesylate in Human Plasma by RP-HPLC
        Authors: Ajitha, A., Sujatha, K., Abbulu, K.
        Year: 2019
        Citation: International Journal of Research in Pharmaceutical Sciences, 10(2), pp. 1314–1320. 🧪🩸
      10. The Identification of Bioactive Compounds from Turbinaria Ornata (Turner) J. Agaradh and Computational Studies
        Authors: Deepa, S., Sujatha, K., Velmurugan, D.
        Year: 2019
        Citation: Pharmacognosy Journal, 11(5), pp. 873–883. 🍃🔍